Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Redeye provides an update following Corline’s Q2 2025 report. Overall, the report contained no major surprises, with sales remaining at relatively low levels and costs under control. Following the report, we have made only minor adjustments to our estimates, leaving our valuation unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/